Theseus Pharmaceuticals, Inc.
DelistedCIK 1745020fmd_02WQ110MKK9368EJ0AHEV3RJ80Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2023, 15 periods
| Line item | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| Research and development | 6 | 18 | 36 |
| Total operating expenses | 7 | 27 | 54 |
| Operating income | (7) | (27) | (54) |
| Other non-operating income (expense) | (5) | 0 | 3 |
| Net income | (12) | (27) | (51) |
| Net income to common shareholders | (12) | (27) | (51) |